Leukemia Translocation Panel for Real-Time PCR

Chromosomal translocations are among the most significant genetic alterations in leukemia and serve as key biomarkers for disease classification, prognosis, and the development of targeted therapies. These translocations often result in the fusion of enhancer/promoter regions or coding sequences from two distinct genes, leading to abnormal gene expression, disruption of normal cellular function, or oncogenic activity that drives leukemogenesis. Specific fusion genes are highly prevalent in both pediatric and adult leukemias and are closely associated with disease progression and treatment response.

Accurate detection and identification of fusion gene transcripts in blood or bone marrow samples are essential for diagnosis, prognostic assessment, and treatment stratification in acute lymphoblastic leukemia (ALL), acute promyelocytic leukemia (APL), and acute myeloid leukemia (AML). Beyond initial detection, quantitative molecular monitoring of these fusion transcripts allows for the identification of minimal residual disease (MRD) and early signs of molecular relapse, supporting timely adjustments to therapeutic approaches

The Leukemia Translocation Panel v2 (LEUKMP) is a quantitative real-time PCR-based assay designed for the sensitive detection and monitoring of 11 fusion gene variants associated with six key chromosomal translocations in ALL, AML, and APL. The assay includes validated primer-probe sets and is compatible with major multi-channel real-time PCR platforms, supporting both diagnostic research and longitudinal MRD monitoring.

A low positive control for the Leukemia Translocation Panel is available and sold separately to support assay validation and performance monitoring.

Additionally, one-step RT-PCR kits for individual fusion gene transcripts are available separately for molecular monitoring during treatment.